End-of-day quote
Other stock markets
|
|
5-day change | 1st Jan Change | |
28,950 KRW | +5.08% | -0.69% | +5.58% |
May. 04 | Caregen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
May. 04 | Caregen's Net Income Jumps 88.2% in Q1 | MT |
Sales 2023 * | 98 0.07 | Sales 2024 * | 155 0.12 | Capitalization | 1,422B 1.08B |
---|---|---|---|---|---|
Net income 2023 * | 37 0.03 | Net income 2024 * | 71 0.05 | EV / Sales 2023 * | 14,5x |
Net cash position 2023 * | 5 0 | Net cash position 2024 * | 27 0.02 | EV / Sales 2024 * | 9,00x |
P/E ratio 2023 * | 38,6x | P/E ratio 2024 * | 20,1x | Employees | 180 |
Yield 2023 * | 1,87% | Yield 2024 * | 1,87% | Free-Float | 27.41% |
More Fundamentals
* Assessed data
More news
1 day | +5.08% | ||
1 week | -0.69% | ||
Current month | +2.48% | ||
1 month | +3.95% | ||
3 months | -32.99% | ||
6 months | -25.35% | ||
Current year | +5.58% |
1 week
27 200.00
29 450.00

1 month
23 000.00
29 700.00

Current year
23 000.00
53 400.00

1 year
23 000.00
53 400.00

3 years
10 080.00
53 400.00

5 years
10 080.00
53 400.00

10 years
10 080.00
53 400.00

Managers | Title | Age | Since |
---|---|---|---|
Yong-Ji Chung
CEO | Chief Executive Officer | 53 | 2001 |
Eun-Mi Kim
CTO | Chief Tech/Sci/R&D Officer | 42 | 2003 |
Hee-Sook Ra
SAM | Sales & Marketing | 50 | 2009 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yong-Ji Chung
CEO | Chief Executive Officer | 53 | 2001 |
Eun-Mi Kim
CTO | Chief Tech/Sci/R&D Officer | 42 | 2003 |
Dae-Ok Kim
BRD | Director/Board Member | 55 | - |
Date | Price | Change | Volume |
---|---|---|---|
23-12-08 | 28,950 | +5.08% | 125,800 |
23-12-07 | 27,550 | -1.25% | 87,974 |
23-12-06 | 27,900 | +1.09% | 78,143 |
23-12-05 | 27,600 | -0.72% | 93,815 |
23-12-04 | 27,800 | -4.63% | 192,858 |
End-of-day quote Korea Stock Exchange, December 07, 2023
More quotes
Caregen Co., LTD is a Korea-based company mainly engaged in the manufacture of cosmeceuticals and dermal fillers. The Company manufactures HSR CEs which used for improving facial wrinkles and strengthening protect wet under the brand name of Dermaheal, aquashines which used for keeping the shin whitening and promoting skin cells activation under the brand name of REVOFIL, HL CEs which used for treating hair loss, hair filler excell C'rums which used for promoting hair growth and preventing hair lose, LL CEs which used for promoting fat decomposition and prevent fat accumulation, hydra B5 Gels, ultra AW500s, eye filler masks, efficacy raw materials including growth facors and biomimetic peptides, and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-02-06
- Q4 2023 Earnings Release (Projected)
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
28,950KRW
Average target price
50,000KRW
Spread / Average Target
+72.71%
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+5.58% | 1 081 M $ | |
+23.41% | 35 534 M $ | |
+29.69% | 20 944 M $ | |
0.00% | 13 229 M $ | |
+13.30% | 11 795 M $ | |
-17.27% | 8 436 M $ | |
+52.05% | 7 746 M $ | |
-0.05% | 6 788 M $ | |
-8.87% | 5 726 M $ | |
-0.70% | 4 969 M $ |